Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by alleyesonmeon Sep 25, 2022 4:05pm
98 Views
Post# 34985292

RE:RE:RE:RE:Jazz Pharmaceutical BUYOUT.

RE:RE:RE:RE:Jazz Pharmaceutical BUYOUT.Wednesday LABS may submit a patent challenge to the FDA on Epidiolex...the review may take upto 180 days from filing...if successful, LABS, using the DEL and the now active FDA masterfile can ship it's CBD 100 formulation under a new name as a generic for Epidiolex...this is the only FDA approved cannabinoid based pharmaceutical in the U.S and is Pure CBD oil taken as such with a price of 1700-2200$ for a 100ml bottle....covered by insurers....... management commentary has stated multiple times they plan on "challenging patents for FDA approved cannabinoid drugs" ...they've taken all necessary steps and obtained all necessary certs for this to happen. This challenge is the last step for this generic offering to become reality....no other company is position for this...I'm expecting a P/R Wednesday or shortly after officially acknowledging the now active FDA masterfile along with the submitted FDA patent challenge for Epidiolex....
<< Previous
Bullboard Posts
Next >>